At the Intersection of Science and Law Podcast Series

In DLA Piper's At the Intersection of Science and Law podcast series, members of the firm's Life Sciences team will explore the connection between science and the law in areas including AI and drug discovery, mRNA technology, and the regulatory implications of new drugs and devices.

Listen to the At the Intersection of Science and Law podcast on iTunes, Stitcher and Spotify.

ISSUES

Global Life Sciences Supply Chain Insights

16 November 2022
At the Intersection of Science and Law Podcast Series
Lauren Murdza and Richard Taylor share their insights on supply chain issues in the life sciences sector in the latest episode of At the Intersection of Science and Law.

AI risk assessments: Future-proofing your innovation when rules can change mid-game

15 September 2022
At the Intersection of Science and Law Podcast Series
Danny Tobey is joined by Aviva Wein to discuss how medical device and pharmaceutical companies are future-proofing their innovations in artificial intelligence as new regulations and risks arise.

The rise of global telehealth

30 June 2022
At the Intersection of Science and Law Podcast Series
Partners Kristi Kung and Greg Bodulovic discuss the rise of telehealth amid the COVID-19 pandemic, as well as advancements in technology aiming to address disparate access to healthcare globally.

Advising the advisor: Tips for navigating the life sciences and regulatory environment

19 April 2022
At the Intersection of Science and Law Podcast Series
Emilio Ragosa is joined by Kevin Sheridan, Joint Global Head of Healthcare Investment Banking at Jefferies LLC, to discuss the importance of advisors having an understanding of the life sciences industry.
The moral imperative: Balancing innovation, regulation and prescription drug availability

21 March 2022
At the Intersection of Science and Law Podcast Series
Jim Greenwood and Geoff Levitt are joined by Peter Kolchinsky to discuss the importance of – and complications in - balancing biopharmaceutical innovation, industry regulations and prescription drug availability.

Incentivizing diverse representation in clinical trials

2 March 2022
At the Intersection of Science and Law Podcast Series
Kirsten Axelsen and Sarah Schick are joined by Shazia Ahmad, Senior Director and Head of Patient and Physician Services at UBC, to discuss the importance of regulatory incentives to drive racial and ethnic diversity in clinical trials.

Telehealth’s impact on low-income communities

24 January 2022
At the Intersection of Science and Law Podcast Series
Shared from our Beyond the Curve podcast series
Ray Williams and Kirsten Axelsen are joined by Dr. Benson Hsu of the University of South Dakota Sanford School of Medicine for a frank discussion on disparities to engaging with telehealth and ways to better serve low income communities. Originally recorded on March 3, 2021.

The crossroad of science and law

16 December 2021
At the Intersection of Science and Law Podcast Series
Lucas Przymusinski and Raymond Williams are joined by Michael King, Vice President and Associate General Counsel at Jazz Pharmaceuticals, to discuss the benefits of medical and science backgrounds when litigating matters for pharmaceutical and medical device companies.

Social media’s impact on the life sciences industry

8 November 2021
At the Intersection of Science and Law Podcast Series
Chris Campbell and Jody Rhodes are joined by Sarah Heineman, Senior Assistant General Counsel at Bayer, to discuss how social media affects the public’s view of medicine and science.

Understanding AI and its use in drug discovery

6 October 2021
At the Intersection of Science and Law Podcast Series
DLA Piper partners Ellen Scordino and Susan Krumplitis are joined by Duane Valz, General Counsel of Insitro, to discuss how machine learning is being used to generate and leverage data for the development of better medicines.
Dr. Lisa Haile talks with Dr. Kathy Fernando about the study of mRNA and how COVID-19 catalyzed its advancement.